363 related articles for article (PubMed ID: 27586690)
21. Edoxaban: a review in nonvalvular atrial fibrillation.
McCormack PL
Am J Cardiovasc Drugs; 2015 Oct; 15(5):351-61. PubMed ID: 26369340
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial.
Vilain K; Li H; Kwong WJ; Antman EM; Ruff CT; Braunwald E; Cohen DJ; Giugliano RP; Magnuson EA;
Circ Cardiovasc Qual Outcomes; 2020 Nov; 13(11):e006511. PubMed ID: 33148013
[TBL] [Abstract][Full Text] [Related]
23. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†.
O'Donoghue ML; Ruff CT; Giugliano RP; Murphy SA; Grip LT; Mercuri MF; Rutman H; Shi M; Kania G; Cermak O; Braunwald E; Antman EM
Eur Heart J; 2015 Jun; 36(23):1470-7. PubMed ID: 25687352
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
Zelniker TA; Ardissino M; Andreotti F; O'Donoghue ML; Yin O; Park JG; Murphy SA; Ruff CT; Lanz HJ; Antman EM; Braunwald E; Giugliano RP; Merlini PA
Circulation; 2021 Feb; 143(7):673-684. PubMed ID: 33587659
[TBL] [Abstract][Full Text] [Related]
25. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
Salazar DE; Mendell J; Kastrissios H; Green M; Carrothers TJ; Song S; Patel I; Bocanegra TS; Antman EM; Giugliano RP; Kunitada S; Dornseif B; Shi M; Tachibana M; Zhou S; Rohatagi S
Thromb Haemost; 2012 May; 107(5):925-36. PubMed ID: 22398655
[TBL] [Abstract][Full Text] [Related]
26. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
[TBL] [Abstract][Full Text] [Related]
27. First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial.
Steffel J; Ruff CT; Hamershock RA; Murphy SA; Senior R; Roy D; Lanz HJ; Mercuri MF; Antman EM; Giugliano RP
Int J Cardiol; 2017 Oct; 244():192-195. PubMed ID: 28625512
[TBL] [Abstract][Full Text] [Related]
28. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
[TBL] [Abstract][Full Text] [Related]
29. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
[TBL] [Abstract][Full Text] [Related]
30. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
Qamar A; Antman EM; Ruff CT; Nordio F; Murphy SA; Grip LT; Greenberger NJ; Yin OQP; Choi Y; Lanz HJ; Mercuri MF; Braunwald E; Giugliano RP
J Am Coll Cardiol; 2019 Jul; 74(2):179-189. PubMed ID: 31296289
[TBL] [Abstract][Full Text] [Related]
31. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.
Boriani G; Ruff CT; Kuder JF; Shi M; Lanz HJ; Rutman H; Mercuri MF; Antman EM; Braunwald E; Giugliano RP
Eur Heart J; 2019 May; 40(19):1541-1550. PubMed ID: 30624719
[TBL] [Abstract][Full Text] [Related]
32. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E
Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226
[TBL] [Abstract][Full Text] [Related]
33. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Brekelmans M; Middeldorp S; Coppens M
Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
[TBL] [Abstract][Full Text] [Related]
34. Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.
Steffel J; Ruff CT; Yin O; Braunwald E; Park JG; Murphy SA; Connolly S; Antman EM; Giugliano RP
J Am Coll Cardiol; 2021 Mar; 77(9):1197-1207. PubMed ID: 33663737
[TBL] [Abstract][Full Text] [Related]
35. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
Bohula EA; Giugliano RP; Ruff CT; Kuder JF; Murphy SA; Antman EM; Braunwald E
Circulation; 2016 Jul; 134(1):24-36. PubMed ID: 27358434
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective.
Vilain KA; Yang MC; Hui Tan EC; Wang K; Li H; Hsu WH; Giugliano RP; Cohen DJ; Magnuson EA;
Value Health Reg Issues; 2017 May; 12():74-83. PubMed ID: 28648320
[TBL] [Abstract][Full Text] [Related]
37. Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
Weitz JI; Eikelboom J
Thromb Haemost; 2016 Jan; 115(2):257-70. PubMed ID: 26466666
[TBL] [Abstract][Full Text] [Related]
38. Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study.
de Groot JR; Ruff CT; Murphy SA; Hamershock RA; Vehmeijer JT; Oude Ophuis AJM; Grip L; Lanz H; Mercuri MF; Antman EM; Giugliano RP
Am Heart J; 2021 May; 235():132-139. PubMed ID: 33493453
[TBL] [Abstract][Full Text] [Related]
39. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Mega JL; Walker JR; Ruff CT; Vandell AG; Nordio F; Deenadayalu N; Murphy SA; Lee J; Mercuri MF; Giugliano RP; Antman EM; Braunwald E; Sabatine MS
Lancet; 2015 Jun; 385(9984):2280-7. PubMed ID: 25769357
[TBL] [Abstract][Full Text] [Related]
40. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Mercuri M; Curt V; Betcher J; Grip L; Cange AL; Crompton AE; Murphy SA; Deenadayalu N; Antman EM
J Am Coll Cardiol; 2014 Aug; 64(6):576-84. PubMed ID: 25104527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]